Free Trial

Illumina (ILMN) Stock Forecast & Price Target

Illumina logo
$136.02 +2.02 (+1.51%)
(As of 12/20/2024 05:51 PM ET)

Illumina - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
8
Buy
12

Based on 20 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 8 have given a hold rating, 10 have given a buy rating, and 2 have given a strong buy rating for ILMN.

Consensus Price Target

$165.95
22.00% Upside
According to the 20 analysts' twelve-month price targets for Illumina, the average price target is $165.95. The highest price target for ILMN is $254.00, while the lowest price target for ILMN is $115.00. The average price target represents a forecasted upside of 22.00% from the current price of $136.02.
Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

Sign Up

ILMN Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
10 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
9 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$165.95$164.00$151.05$179.10
Forecasted Upside22.00% Upside17.03% Upside16.10% Upside27.93% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Illumina Stock vs. The Competition

TypeIlluminaMedical CompaniesS&P 500
Consensus Rating Score
2.70
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside22.00% Upside25,827.51% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent ILMN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/11/2024Citigroup
3 of 5 stars
P. Donnelly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$190.00 ➝ $165.00+11.09%
11/12/2024Stephens
4 of 5 stars
 Boost TargetOverweight ➝ Overweight$170.00 ➝ $184.00+21.45%
11/12/2024Morgan Stanley
3 of 5 stars
 Reiterated RatingEqual Weight$156.00+2.97%
11/11/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$195.00 ➝ $185.00+22.44%
11/6/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$124.00 ➝ $139.00-10.30%
11/5/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Brennan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$166.00 ➝ $177.00+15.02%
11/5/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$133.00 ➝ $145.00-4.89%
11/5/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$252.00 ➝ $254.00+68.04%
11/5/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$125.00 ➝ $140.00-7.76%
11/5/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$135.00 ➝ $145.00-3.65%
11/5/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$130.00 ➝ $145.00-5.53%
10/17/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Gupta
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy$180.00+25.42%
10/17/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$160.00 ➝ $200.00+38.91%
10/17/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$180.00+25.10%
8/28/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$150.00+14.59%
8/16/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/16/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$120.00 ➝ $154.00+19.57%
8/15/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Outperform ➝ Sector Outperform$176.00 ➝ $164.00+27.33%
6/11/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$195.00 ➝ $175.00+59.35%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$115.00+10.28%
3/20/2024OTR Global
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingPositive ➝ Mixed
12/15/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform
12/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$155.00+22.37%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$175.00+48.76%
12/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$140.00 ➝ $100.00-14.99%
10/12/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$200.00+49.91%
8/10/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$225.00 ➝ $200.00+8.41%
1/10/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$350.00 ➝ $296.00+42.78%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:09 PM ET.


Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 12, 2024. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

Illumina
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • Illumina, Inc. recently reported earnings per share (EPS) of $1.14, surpassing analysts' expectations of $0.88, indicating strong financial performance and potential for growth.
  • The company has a solid current ratio of 2.43, which suggests it has more than enough assets to cover its short-term liabilities, reflecting good financial health.
  • Illumina's stock price is currently at $139.91, showing resilience in the market despite fluctuations, which may attract investors looking for stability.
  • Institutional investors hold a significant 89.42% of Illumina's stock, indicating strong confidence from large financial entities in the company's future prospects.
  • Recent increases in holdings by various institutional investors, such as Worldquant Millennium Advisors LLC, which raised its stake by 31%, suggest positive sentiment and potential for further stock appreciation.

Illumina
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • Illumina reported a negative net margin of 36.10%, indicating that the company is currently spending more than it earns, which could raise concerns about profitability.
  • The company's revenue decreased by 3.5% year-over-year, suggesting potential challenges in maintaining sales growth in a competitive market.
  • Despite recent positive earnings, the stock has experienced volatility, with a 52-week low of $100.08, which may deter risk-averse investors.
  • Illumina's debt-to-equity ratio stands at 0.94, which, while not excessively high, indicates that the company is using a significant amount of debt to finance its operations, potentially increasing financial risk.
  • Recent selling by Verition Fund Management LLC, which decreased its stake by 38.5%, may signal a lack of confidence from some investors, raising red flags for potential buyers.

ILMN Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $165.95, with a high forecast of $254.00 and a low forecast of $115.00.

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 8 hold ratings, 10 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ILMN shares.

According to analysts, Illumina's stock has a predicted upside of 22.00% based on their 12-month stock forecasts.

Over the previous 90 days, Illumina's stock had 2 upgrades and 1 downgrade by analysts.

Analysts like Illumina less than other "medical" companies. The consensus rating score for Illumina is 2.70 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ILMN compares to other companies.


This page (NASDAQ:ILMN) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners